ArticleStem cell reviews and reports2015
Novel Small Molecule Inhibitors of Cancer Stem Cell Signaling Pathways.
Article in Stem cell reviews and reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 23 citations in OpenAlex.
- Fate decisions of breast cancer stem cells in cancer progression.Frontiers in oncology · 2022Review
- Signaling pathways governing breast cancer stem cells behavior.Stem cell research & therapy · 2021Review
- The hedgehog pathway regulates cancer stem cells in serous adenocarcinoma of the ovary.Cellular oncology (Dordrecht, Netherlands) · 2020Article
- The Relevance of Transcription Factors in Gastric and Colorectal Cancer Stem Cells Identification and Eradication.Frontiers in cell and developmental biology · 2020Review
- Targeting of Lung Cancer Stem Cell Self-Renewal Pathway by a Small Molecule Verrucarin J.Stem cell reviews and reports · 2019Article
- Application of Nanotechnology in Targeting of Cancer Stem Cells: A Review.International journal of stem cells · 2019Review
- PD-L1 Expression on Lung Cancer Stem Cells in Metastatic Lymph Nodes Aspirates.Stem cell reviews and reports · 2019Article
- Targeting Strategies for the Combination Treatment of Cancer Using Drug Delivery Systems.Pharmaceutics · 2017Review
- Properties and feasibility of using cancer stem cells in clinical cancer treatment.Cancer biology & medicine · 2016Article
- Drug Delivery Using Nanoparticles for Cancer Stem-Like Cell Targeting.Frontiers in pharmacology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The main aim of oncologists worldwide is to understand and then intervene in the primary tumor initiation and propagation mechanisms. This is essential to allow targeted elimination of cancer cells without altering normal mitotic cells. Currently, there are two main rival theories describing the process of tumorigenesis. According to the Stochastic Model, potentially any cell, once defunct, is capable of initiating carcinogenesis. Alternatively the Cancer Stem Cell (CSC) Model posits that only a small fraction of undifferentiated tumor cells are capable of triggering carcinogenesis. Like healthy stem cells, CSCs are also characterized by a capacity for self-renewal and the ability to generate differentiated progeny, possibly mediating treatment resistance, thus leading to tumor recurrence and metastasis. Moreover, molecular signaling profiles are similar between CSCs and normal stem cells, including Wnt, Notch and Hedgehog pathways. Therefore, development of novel chemotherapeutic agents and proteins (e.g., enzymes and antibodies) specifically targeting CSCs are attractive pharmaceutical candidates. This article describes small molecule inhibitors of stem cell pathways Wnt, Notch and Hedgehog, and their recent chemotherapy clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.